Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Assessment of the Early Efficacy Response Rate of Leflunomide According to the Initial Dosing Regimen in the Treatment of Naive-DMARD (Disease Modifying Anti-Rheumatic Drug) Early RA (Rheumatoid Arthritis)-Patients.

Trial Profile

Assessment of the Early Efficacy Response Rate of Leflunomide According to the Initial Dosing Regimen in the Treatment of Naive-DMARD (Disease Modifying Anti-Rheumatic Drug) Early RA (Rheumatoid Arthritis)-Patients.

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Nov 2016

At a glance

  • Drugs Leflunomide (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms LEADER
  • Sponsors Sanofi
  • Most Recent Events

    • 12 Oct 2010 Actual end date changed from Sep 2009 to Oct 2009 as reported by ClinicalTrials.gov.
    • 17 Jun 2010 Results presented at the 11th Annual Congress of the European League Against Rheumatism.
    • 11 Nov 2009 Actual end date (1 Sep 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top